Chen Steven L, Clark Samuel, Pierce Lori J, Hayes Daniel F, Helvie Mark A, Greeno Paula L, Newman Lisa A, Chang Alfred E
University of Michigan Center for Health Care Economics, Ann Arbor 48109, USA.
Cancer. 2004 Sep 1;101(5):1043-50. doi: 10.1002/cncr.20476.
The current study sought to determine the institutional financial impact of a screening mammography (SM) program in the context of an integrated cancer center.
Using administrative databases, 10,048 women were identified as receiving screening mammograms in fiscal year 1999 and the first one-half of fiscal year 2000. The utilization of breast care resources was followed for an average of 1208 days. The University of Michigan cost accounting system was then used to determine overall margin (revenues-total costs) and contribution margin (revenues-actual costs) of the SM program, as well as other breast care services.
The percentage of variable costs to total costs for the SM program was 24%. The overall facility losses in the breast care line were $1.7 million with a positive contribution margin of $2.0 million. The annual yield of nonscreening/diagnostic mammographic procedures was 0.9%. All types of radiologic activity failed to cover their total costs, but did provide a positive contribution margin. Overall margins for surgery procedures were approximately even, and adjuvant medical and radiotherapy services were net positive. Modeling helped to identify overhead limits necessary to achieve margin targets associated with increased activity.
The current study showed that SM programs are unlikely to succeed financially without careful selection of those screened to increase the yield of diagnostic and therapeutic procedures. Based on favorable contribution margins, SM programs were viable when viewed as incremental business.
本研究旨在确定在综合癌症中心背景下,乳腺筛查钼靶(SM)项目对机构财务的影响。
利用管理数据库,确定了10,048名在1999财年和2000财年上半年接受乳腺筛查钼靶检查的女性。对她们乳腺护理资源的使用情况进行了平均1208天的跟踪。然后使用密歇根大学成本核算系统来确定SM项目以及其他乳腺护理服务的总利润(收入-总成本)和边际贡献(收入-实际成本)。
SM项目可变成本占总成本的百分比为24%。乳腺护理业务线的总体设施亏损为170万美元,边际贡献为200万美元。非筛查/诊断性乳腺钼靶检查的年产量为0.9%。所有类型的放射学活动都未能覆盖其总成本,但确实提供了正的边际贡献。手术程序的总体利润大致持平,辅助医疗和放疗服务为净盈利。建模有助于确定实现与活动增加相关的利润目标所需的间接费用上限。
当前研究表明,如果不仔细筛选受检者以提高诊断和治疗程序的产量,SM项目在财务上不太可能成功。基于有利的边际贡献,当将SM项目视为增量业务时是可行的。